<DOC>
	<DOCNO>NCT00538668</DOCNO>
	<brief_summary>The purpose study test safety experimental drug , 177Lu-J591 see effect ( good bad ) prostate cancer . Another purpose find high dose drug give without cause severe side effect .</brief_summary>
	<brief_title>Radioimmunotherapy Prostate Cancer Using 177Lu-J591 Antibody</brief_title>
	<detailed_description>Study Design : We plan perform phase I dose-escalation study . The trial design determine cumulative MTD FDR 177Lu-J591 give 2 dos , 2 week apart . The dose escalation start 20 mCi/m2 escalate increment 5 mCi/m2 55 mCi/m2 8 cohorts.We plan recruit maximum 68 subject trial . Specific Aims : 1 . Determine cumulative MTD 177Lu-J591 2 week dose-fractionation regimen . 2 . Perform image pharmacokinetic ( PK ) study 177Lu-J591 order define PK dosimetry 177Lu-J591 3 . Determine myelotoxicity fractionate dose 177Lu-J591 4 . Monitor biochemical ( PSA ) and/or measurable disease response duration . Following administration 177Lu-J591 mAb day 0 , blood sample may obtain 10 min , 1 , 2 , 4 hr , day 1 , day 3-6 , day 7 14 . In addition , total body image may obtain day 0 1-4 hour study treatment , day 1 , day 3-6 , day 7 14 use gamma camera . ( Amendment date 15 July 2009 : As investigator gain ample information initial cohort , PK 177Lu-J591 image study ( day 6-8 scan ) consider optional . ) Patients follow minimum 12 week 2nd dose 177Lu-J591 ( total 14 week ) toxicity resolve , disease progression administration alternative therapy patient¿s prostate cancer . Various clinical laboratory evaluation perform first week every week 12 week . These include , blood chemistry , CBCs , serum PSA level , etc . If patient¿s disease stable respond 12 week last dose , continue follow progression disease . During long-term follow-up , patient¿s PSA monitor least every 6 week CT/bone scan evaluate least every 18 week disease progression .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>1 . Histologic diagnosis ( recent remote ) prostate adenocarcinoma . 2 . Progressive , castrate metastatic carcinoma prostate define presence metastatic disease imaging : progressive tumor lesion CT MRI and/or new osseous lesion bone scan and/or rise PSA 3 . Rising PSA 3 serial determination period ≥ 2 week . 4 . If patient treat LHRH analog , drug : must maintain duration study must terminate ≥ 10 week prior entry ( 28 day depot preparation ) 24 week ( 3 month depot preparation ) 32 week ( 4 month depot preparation ) . 5 . Platelet count &gt; 150,000/mm3 . 6 . Absolute neutrophil count ( ANC ) ≥ 2,000/mm3 7 . Normal coagulation profile ( PT , PTT ) , unless stable anticoagulation regimen 8 . Hematocrit &gt; 30 % Hemoglobin &gt; 10g/dL without blood transfusion dependency 9 . Patients child bear potential must agree use effective method contraception . 10 . Patient must progress follow discontinuation antiandrogen therapy , receive . 11 . Serum testosterone &lt; 50 ng/ml . 1 . Prior aspirin and/or nonsteroidal antiinflammatory agent within 1 week study treatment . 2 . Prior corticosteroid and/or adrenal hormone inhibitor within 4 week treatment , except low dose maintenance prednisone hydrocortisone ( i.e . adrenal insufficiency ) stable dose investigator 's discretion . 3 . Prior cytotoxic chemotherapy and/or radiation therapy within 4 week treatment . 4 . Prior radiation therapy encompass &gt; 25 % expect red marrow distribution . 5 . Prior treatment 89Strontium ( Metastron® ) 153Samarium ( Quadramet® ) . CNS metastasis . 6 . History seizure and/or stroke within past 2 year 7 . History HIV 8 . Serum creatinine &gt; 2.0 9 . SGOT &gt; 2x ULN 10 . Bilirubin ( total ) &gt; 1.5x ULN 11 . Serum calcium &gt; 12.5 12 . Active infection 13 . Active angina pectoris NY Heart Association Class IIIIV . 14 . Karnofsky Performance Status &lt; 60 ; ECOG Performance Status &gt; 2 . 15 . Life expectancy &lt; 6 month 16 . Other serious illness ( e ) involve cardiac , respiratory , CNS , renal , hepatic hematological organ system might preclude completion study interfere determination causality adverse effect experience study . 17 . Prior treatment monoclonal Ab J591 label therapeutic dos 177Lu 90Y 18 . Other investigational therapy within 4 week treatment</criteria>
	<gender>Male</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Prostate</keyword>
	<keyword>Prostate Cancer</keyword>
	<keyword>Prostate Ca</keyword>
</DOC>